MedTrace Logo

Prediction of Everolimus-induced Interstitial Lung Disease

NCT01978171 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2018-04-12

No results posted yet for this study

Summary

The investigators will determine which factors are predictive for the development and severity of everolimus-induced interstitial lung disease and will develop a prediction model based on these risk factors.

Conditions

  • Breast Neoplasms

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Carla van Herpen, MD, PhD · Radboud university medical center, department of medical oncology

  • Nielka van Erp, PharmD, PhD · Radboud university medical center, department of Pharmacy

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-01-15
Completion
2018-01-15

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01978171 on ClinicalTrials.gov